Relief Therapeutics Holding SA
OTC:RLFTY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Relief Therapeutics Holding SA
OTC:RLFTY
|
CH |
|
Orient Cement Ltd
NSE:ORIENTCEM
|
IN |
|
G
|
Green Technology Metals Ltd
OTC:GTMLF
|
AU |
|
C
|
Champion Iron Ltd
ASX:CIA
|
AU |
|
C
|
Carpenter Technology Corp
F:XTY
|
US |
|
S
|
Smurfit Kappa Group PLC
SWB:SK3
|
IE |
|
V
|
Vodafone Group PLC
XMUN:VODI
|
UK |
|
Lamar Advertising Co
NASDAQ:LAMR
|
US |
|
P
|
PayPal Holdings Inc
XETRA:2PP
|
US |
|
E
|
Embotelladora Andina SA
SWB:AKOB
|
CL |
|
A
|
Azimut Holding SpA
SWB:HDB
|
IT |
|
V
|
Vodafone Group PLC
DUS:VODI
|
UK |
|
B
|
Barry Callebaut AG
XBER:BCLN
|
CH |
|
Southwest Airlines Co
NYSE:LUV
|
US |
|
B
|
Beyond Securities PCL
SET:BYD
|
TH |
|
H
|
Hyatt Hotels Corp
XBER:1HTA
|
US |
|
S
|
Skechers USA Inc
SWB:SKAA
|
US |
|
F
|
Fraport AG Frankfurt Airport Services Worldwide
XBER:FRA
|
DE |
|
P
|
Pultegroup Inc
DUS:PU7
|
US |
|
Empresa Distribuidora y Comercializadora Norte SA
NYSE:EDN
|
AR |
|
N
|
National Retail Properties Inc
F:CZ2
|
US |
|
A
|
Asics Corp
SWB:ASI1
|
JP |
|
W
|
Wartsila Oyj Abp
DUS:MTA
|
FI |
|
N
|
Nokia Oyj
SWB:NOAA
|
FI |
Relief Therapeutics Holding SA
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
